替格瑞洛对急性冠脉综合征患者安全性和有效性的初步评价

摘要

Objective: To observe the effect of oral administration of ticagrelor in patients with acute coronary syndrome (ACS) clinical efficacy and safety.Methods:196 cases of ACS patients in our hospital, into control group of 98 cases (clopidogrel group) and treatment group (the effect of ticagrelor group 98 cases were randomized according to the order of admission, 6 months observation observed 2 groups of patients with major adverse cardiovascular events (MACE) and during the treatment of complication, and the influence on the blood uric acid in the liver and kidney function.Results:In the clopidogrel group mace rate was significantly greater than that of ticagrelor group (P<0.05); two groups had no serious bleeding complications, mild hemorrhage formation rate difference was not statistically significant (P>0.05); ticagrelor group have 5 patients with dyspnea, weakness, and withdrawal; two groups of liver function (alanine aminotransferase, ALT), renal function (serum creatinine (CR) and blood uric acid (UA) without significant effect (P>0.05).Conclusion:The treatment of ACS for Grillo can significantly reduce the incidence of MACE, and can not increase the risk of severe bleeding, safe and effective clinical application.%目的：观察口服替格瑞洛对急性冠脉综合征（ACS）的临床疗效及安全性。方法：选择我院ACS患者196例，按入院顺序随机分为对照组(氯吡格雷组)98例和治疗组(替格瑞洛组)98例，观察6个月，观察2组患者主要不良心血管事件(MACE)及治疗期间并发症发生以及对肝肾功能血尿酸的影响情况。结果：氯吡格雷组MACE发生率明显大于替格瑞洛组（P＜0.05)；两组均无严重出血并发症，轻度出血发生率差异无统计学意义(P＞0.05)；替格瑞洛组有5例因呼吸困难、乏力而停药；两组对肝功能(丙氨酸氨基转移酶,ALT)肾功能（血肌酐，Cr）及血尿酸(UA)无明显影响，P＞0.05。结论：替格瑞洛治疗ACS，可明显减少MACE发生率，对严重出血风险无增加，临床应用安全有效。